GSE228261 elesclomol WSU-DLCL2 0 v 1 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE228261_elesclomol_WSU-DLCL2_0_v_1_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE228261_elesclomol_WSU-DLCL2_0_v_1_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE228261_elesclomol_WSU-DLCL2_0_v_1_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE228261_elesclomol_WSU-DLCL2_0_v_1_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

mitochondrial ribosomal protein S18B

Gene

NBPF member 8

Gene

uncharaterized LOC112694756

Gene

leukocyte receptor cluster member 9

Gene

CENPB DNA-binding domains containing 2, pseudogene

Gene

uncharacterized LOC124901321

Gene

ITGB2 antisense RNA 1

Gene

INSIG1 divergent transcript

Gene

small nucleolar RNA host gene 20

Gene

long intergenic non-protein coding RNA 2870

  • Gene

    mitochondrial ribosomal protein S18B



  • Gene

    uncharaterized LOC112694756


  • Gene

    leukocyte receptor cluster member 9


  • Gene

    CENPB DNA-binding domains containing 2, pseudogene


  • Gene

    uncharacterized LOC124901321


  • Gene

    ITGB2 antisense RNA 1


  • Gene

    INSIG1 divergent transcript


  • Gene

    small nucleolar RNA host gene 20


  • Gene

    long intergenic non-protein coding RNA 2870

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.